Company History Allarity

Therapeutics was founded as Medical Prognosis Institute A/S in Denmark in 2004 by Professor Steen Knudsen, Ph.D., a pioneer in computational biology. Since 1996, Knudsen has been instrumental in building the Center for Biological Sequence Analysis at the Technical University of Denmark (DTU). His research, based on bioinformatics, explored the potential of using gene chips to fight cancer. Knudsen established Medical Prognosis Institute A/S (MPI) to bring this discovery to cancer patients in 2004 as a spin-out from DTU, with DTU Innovation A/S as the primary investor.

MPI initially focused on identifying the most promising clinical uses of gene chips, with an early emphasis on lung cancer prognostics. By 2006, MPI made a significant breakthrough: comparing data from the U.S. National Cancer Institute (NCI) allowed the prediction of which patients would benefit from chemotherapy. This development led to a patent application, which was approved by the American patent authorities in 2013. The company gradually shifted towards commercialization, selling (partnering?) its Drug Response Predictor (DRP®) technology to pharmaceutical and biotech companies.

Renamed Oncology Venture A/S, the company began to focus on drug development and collaboration with pharma and biotech companies. In 2020, the company rebranded as Allarity Therapeutics. By the end of 2021, it transitioned from a Danish entity listed in Sweden to a U.S. corporation on the Nasdaq stock market. In 2024, Allarity narrowed its focus to developing stenoparib for treating advanced, recurrent ovarian cancer patients.

Company Overview

Allarity Therapeutics is a pioneering clinical-stage precision medicine company headquartered in Boston, Massachusetts. Specializing in oncology (the study and treatment of cancer), Allarity focuses on developing personalized cancer treatments. This approach tailors therapies to individual patients based on the unique gene expression profiles of each patient’s tumor, aiming to enhance treatment efficacy and minimize adverse effects. The company’s mission is to revolutionize cancer care by providing targeted therapies that address significant unmet medical needs in the oncology sector.

One of the core technologies driving Allarity’s innovative approach is its Drug Response Predictor (DRP®) platform. This technology analyzes gene expression data directly from tumor tissue of the cancer patient to predict clinical benefit from specific cancer treatments. This personalized approach represents a significant advancement over traditional one-size-fits-all cancer treatments based only on the cancer type of diagnosis.

Allarity’s lead therapeutic candidate, stenoparib, exemplifies the company’s cutting-edge approach. Stenoparib is a dual inhibitor of PARP (poly ADP ribose polymerase) and tankyrase enzymes, both of which are involved in cancer cell survival and proliferation. Recently showing proof of concept in a Phase 2 clinical trial for advanced, recurrent ovarian cancer, stenoparib targets and disables a cancer cell’s DNA repair mechanisms, selectively killing the cancer cell. Additionally, stenoparib is being co-developed with a drug-specific DRP® companion diagnostic to select and treat patients most likely to benefit from the treatment.

Source: Company Reports

For investors, Allarity’s potential lies not only in its innovative therapy, stenoparib, but also in its strategic market position, leveraging its core technology, DRP, to drive valuable partnerships. By collaborating with innovative partners and leveraging its proprietary Drug Response Predictor (DRP®) technology, Allarity can accelerate the development of numerous anti-cancer drugs.

Through advancing its lead drug candidate, stenoparib, Allarity positions itself at a pivotal point, poised for significant growth based on successful trial outcomes. As Allarity continues to develop stenoparib, the company is poised to make a meaningful impact in the fight against cancer. With the potential for high growth in the biotech sector, Allarity presents a compelling investment opportunity.

Allarity Therapeutics' DRP® (Drug Response Predictor) technology is at the forefront of personalized cancer treatment. This proprietary diagnostic platform enables Allarity to score any tumor’s gene expression profile and to then leverage that profile to identify active, effective treatments for that specific patient. Built on a foundation of systems biology, the DRP® platform analyzes all transcriptional (RNA) changes in tumor cells in response to various drug types, refined with gene expression data from over 3,000 patient tumors. This comprehensive approach provides a detailed picture of how each patient's tumor responds to different therapies, enabling more precise and effective treatment plans.

The DRP® technology's strength lies in its sophisticated understanding of the multiple genetic and transcriptional changes occurring in most cancers. By leveraging millions of data points and advanced transcriptional profiling, the DRP® algorithm can pinpoint a vast range of biomarkers for drug response or resistance. This process includes a clinical relevance filter to eliminate unnecessary biomarkers, ensuring only the most relevant factors are considered. Unlike other biomarker approaches that may be limited by pre-existing knowledge, the DRP® system is not constrained by these limitations, allowing it to identify unknown biomarkers, thereby significantly influencing treatment outcomes.

Source: Company Reports

Evaluated in over 35 clinical trials across various cancer types and drug classes, the DRP® platform has demonstrated an impressive predictive accuracy of over 80% for identifying patient responders. Its efficacy spans a broad array of drug types, including targeted kinase inhibitors, epigenetic inhibitors, chemotherapeutics, and DNA repair inhibitors, as well as a wide range of solid and liquid tumors. This extensive validation underscores the DRP® technology's versatility and reliability in guiding treatment decisions.

The practical applications of the DRP® technology are vast, extending beyond Allarity's clinical pipeline to a wide range of anti-cancer drugs currently approved or in development across the industry. By matching the right drug to the right patient, DRP® technology may enhance therapeutic outcomes, limiting application of ineffective treatments and thereby avoiding unnecessary toxicities. This advancement marks a significant step towards the true era of personalized cancer medicine, where treatments are tailored to the individual characteristics of each patient's tumor.

For patients, the value of DRP® companion diagnostics is potentially immense. Starting early therapy with an effective drug can significantly impact treatment outcomes. This personalized approach may help avoid ineffective therapies, improving the overall quality of care and patient experience. Currently, Allarity Therapeutics focuses on developing stenoparib in conjunction with a dedicated DRP® for stenoparib. However, the DRP technology itself is widely applicable to other cancer drugs, enhancing the potential for personalized treatment strategies across various cancer types.

Why Partner With Allarity?

For drug development partners, DRP® technology offers a strategic advantage. With less than 5% of cancer drugs in clinical development expected to achieve market approval, partnering with Allarity Therapeutics and using the DRP® platform can make clinical development more efficient. By identifying patients who are more likely to respond to a drug candidate, the risk of failure is reduced, and the pathway to market is streamlined, saving time and costs.

Please watch the two-minute video (below) for a simplified overview of DRP Technology.

Source: YouTube

Cancer is an extremely complex and heterogeneous disease characterized by numerous genetic and molecular variations that influence how tumors grow and respond to treatment. Understanding and addressing this complexity is crucial in the development of effective cancer therapies. Allarity Therapeutics' DRP® (Drug Response Predictor) platform is designed to tackle this challenge head-on, using advanced systems biology to analyze the transcriptional landscape of cancer.

At the heart of the DRP® platform is systems biology, a comprehensive approach that examines all genes (approximately 25,000) expressed in a cancer cell or tumor. Unlike traditional methods that may focus on specific known drug targets or pathways, the DRP® platform remains unbiased, allowing it to uncover previously unknown factors that influence drug response. This holistic analysis provides a more complete picture of the tumor's biology and its interaction with different treatments.

The process begins with drug testing data from cancer cell lines. This data is then fed into the DRP® engine, which uses systems biology analysis to filter human tumor biopsy data. The result is a DRP® signature—a unique gene expression profile for a specific drug, ranging from 50 to 400 genes. This signature helps predict how a patient's tumor may respond to a particular therapy. Currently, Allarity Therapeutics is focused on using this method to help advance stenoparib as a treatment for advanced ovarian cancer patients- patients who have been pre-screened using the DRP® to identify those with a high likelihood of responding to the stenoparib.

Source: Company Documents

By allowing the tumor itself to reveal what is most important for drug response, the DRP® platform can identify critical biomarkers that might be missed by conventional approaches. This ability to discover unknown gene expression changes is a key advantage of the DRP® technology, providing superior insights into cancer biology and treatment.

The complexity of cancer requires such advanced tools to personalize therapy effectively. The DRP® platform’s detailed gene expression analysis and its ability to model human tumor biology make it a powerful tool in the fight against cancer. It helps ensure that patients receive the right drug at the right time, maximizing therapeutic benefit and minimizing unnecessary treatments and side effects.

Allarity Therapeutics employs its advanced Drug Response Predictor (DRP®) technology to innovate and improve cancer drug development. Historically, cancer drug development is laborious and expensive as cancer drugs are often evaluated in broad patient populations defined primarily by the tumor’s tissue of origin (ovary, colon, breast, lung, etc.). These trials typically treat all patients with the same diagnosis the same way and do not take into account any of the particularities of each patient’s cancer. As such, the trials are imprecise and will enroll far more patients than necessary, capturing those whose tumors may be sensitive to a therapy as well as the many that would not. This approach leads to large, complicated, lengthy clinical trials- trials where the clinical benefit signal is often masked by the “noise” of treating patients indiscriminately.

The DRP® platform changes this approach. DRP pre-screens patients to assess whether that patient’s cancer has the gene expression changes (the “DRP signature”) that meaningfully indicate that the patient would benefit from therapy. By selecting and enriching for those whose tumors are most likely sensitive to therapy, Allarity’s DRP technology streamlines cancer drug development by enabling clinical trials in ONLY those patients who are most likely to achieve clinical benefit. By streamlining development in this manner, drug development programs that deploy and leverage the DRP approach are quicker and have a higher likelihood of achieving clinical and regulatory success.

The DRP® platform uses a systems biology approach to analyze the genetic landscape of cancer cells. By examining all genes expressed in a tumor, the DRP® technology identifies the genetic changes most critical for drug response. The DRP® engine then generates a drug-specific signature to predict how a patient’s tumor is likely to respond to a particular treatment.

Source: Company Reports

The effectiveness of the DRP® platform has been demonstrated in 47 clinical trials across various cancer types and drug categories. These trials exemplify the DRP® technology's ability to accurately predict patient responses to different treatments, underscoring the potential of DRP® technology to pre-identify potential patient benefit and to improve clinical outcomes. Currently, Allarity Therapeutics is using this advanced technology to demonstrate that its lead asset, stenoparib, can achieve significant, durable clinical benefit in advanced, recurrent ovarian cancer patients who have been pre-selected using the stenoparib-specific DRP®.

Source: Company Reports

Allarity successfully in-licensed stenoparib, a promising drug candidate from Eisai Co. Ltd in Japan to develop alongside its accompanying DRP® technology. Many drugs originally developed by big pharma have failed to show significant clinical benefit in broad, unselected patient populations. Allarity’s DRP technology can identify the right patient populations for these novel cancer drugs, enabling more effective and successful drug development.

Source: Company Reports

Allarity Therapeutics is committed to advancing cancer precision medicine through strategic partnerships and collaborations. By leveraging its proprietary DRP® (Drug Response Predictor) platform, Allarity can work with institutions and companies to co-develop, co-fund, and market innovative cancer treatments. The company considers these collaborations vital for accelerating the development of new therapies and bringing them to patients more quickly and effectively.

The company's partnership efforts focus on business development (BD) deals with a series of early-stage assets to help streamline their development. By partnering with other biotech and pharmaceutical companies, Allarity seeks to share resources and expertise to advance clinical programs more efficiently. These collaborations help mitigate risks and enhance the potential for successful outcomes in clinical trials.

Overview of Stenoparib

Stenoparib is a promising drug candidate originally developed by Eisai Pharmaceuticals and in-licensed by Allarity Therapeutics. Allarity holds exclusive global rights for the commercialization of stenoparib, originally developed by Eisai Co. Ltd. and formerly known as E7449 and 2X-121. Stenoparib is currently being developed as a monotherapy treatment for patients with advanced, recurrent ovarian cancer. The. Drug targets both PARP and tankyrase enzymes, which are involved in DNA repair and the Wnt signaling pathway, respectively. It is an orally available, small-molecule, dual inhibitor of PARP1/2 (poly ADP-ribose polymerase) and Tankyrase 1/ 2, which play crucial roles in DNA repair and cancer cell survival, respectively.

The drug's dual inhibitory activity exploits the vulnerabilities of cancer cells, particularly those with deficient DNA repair mechanisms, leading to their selective death while sparing normal cells. Stenoparib has shown potential in preclinical models and early clinical trials, positioning it as a potential breakthrough therapy in oncology.

In May 2024, Allarity Therapeutics announced the early discontinuation of patient enrollment for its Phase 2 clinical trial of stenoparib for advanced, recurrent ovarian cancer based on the substantial clinical benefit observed in enrolled patients. The trial, which involved pre-screening patients with Allarity’s DRP® companion diagnostic (CDx), demonstrated clear clinical benefit, including tumor shrinkage and long-term disease stability and provided sufficient clinical proof of concept for stenoparib as twice daily monotherapy, prompting Allarity to streamline its clinical portfolio to accelerate stenoparib development in a follow-on trial with FDA regulatory intent. This follow-on trial is currently under development with the Principal Clinical Investigators involved.

Thomas Jensen, CEO of Allarity Therapeutics, stated, “Based on the substantial clinical benefit observed in the early stages of the trial, we have achieved proof of concept results that surpassed our initial expectations and provided the critical insights we were seeking. Concluding the trial now is the most effective way to re-allocate our financial resources to develop a follow-on trial with the fastest route to regulatory submission for stenoparib.”

Further updates in June 2024 highlighted the continued durability of clinical benefit from stenoparib, with multiple patients in the Phase 2 trial exceeding 30 weeks on treatment. This extended clinical benefit underscores the potential of stenoparib to provide significant therapeutic benefits to patients who have limited treatment options. Dr. Kathleen N. Moore, Principal Investigator for the trial, emphasized the importance of developing next-generation PARP inhibitors like stenoparib for patients who do not benefit significantly from existing treatments.

Market Position and Potential

The PARP inhibitor market has seen notable shifts and growth, with an expected market value of $22 billion by 2028. Stenoparib's unique dual inhibition of PARP and Tankyrase enzymes offers a differentiated approach, potentially addressing the unmet needs in ovarian cancer treatment with a more favorable safety profile when compared to first-generation PARP inhibitors. The safety and efficacy demonstrated in early clinical trials position stenoparib as a potential compelling therapeutic candidate even in this competitive landscape.

Background Information about the Trial

The Phase 2 trial of stenoparib is a prospective, open-label, single-arm study conducted at multiple sites in the US and UK. Women with advanced, recurrent ovarian cancer were pre-screened using Allarity’s DRP® companion diagnostic (CDx), which includes a complex transcriptomic signature of 414 mRNA biomarkers. Patients with DRP scores above 50, indicating a higher likelihood of benefiting from treatment, were selected for enrollment to receive stenoparib. The revised dosing regimen to twice daily was implemented in Q1 2023.

Mechanism of Action

Stenoparib’s dual mechanism of action involves inhibiting both PARP and Tankyrase enzymes. PARP inhibitors prevent cancer cells from repairing DNA damage, causing these cells to accumulate damage and eventually die. This mechanism is particularly effective in cancers with BRCA mutations, where DNA repair pathways are already compromised. Tankyrase inhibitors, on the other hand, disrupt the Wnt signaling pathway, a key oncogenic signaling pathway that is overactive in many cancer types and enables cancer cell growth and survival.

By targeting both of these pathways, stenoparib offers a powerful, differentiated, multifaceted approach to cancer therapy.

Source: Company Documents

Preclinical and Early Clinical Development

Preclinical studies of stenoparib demonstrated significant anti-tumor activity in various cancer models, including ovarian, breast, and pancreatic cancers. These studies showed that stenoparib effectively induces cell death in cancer cells while minimizing damage to normal cells. Early-phase clinical trials further validated these findings, showing promising results with acceptable safety profiles. Patients with advanced solid tumors treated with stenoparib exhibited preliminary evidence of anti-tumor activity, paving the way for more extensive clinical evaluation.

Phase 2 Trial

Stenoparib recently reached proof of concept in a Phase 2 clinical trial to evaluate its efficacy and safety in patients with advanced, recurrent ovarian cancer. The early data marks a significant step forward in developing stenoparib, reflecting Allarity’s dedication to advancing this promising therapy to address the urgent needs of advanced ovarian cancer patients. Further details and comprehensive data are intended to be presented at a high-level scientific conference.

Dual Inhibition Strategy with Stenoparib

The dual inhibition strategy of stenoparib targets two critical pathways in cancer biology: DNA repair and Wnt signaling. By inhibiting PARP, stenoparib exploits the synthetic lethality in cancer cells with defective DNA repair mechanisms, such as those with BRCA mutations, which leads to the accumulation of DNA damage and cancer cell death.

In parallel, the inhibition of Tankyrase disrupts the Wnt signaling pathway, which is often upregulated in various cancers and contributes to tumor growth and metastasis. This dual approach enhances the drug’s anti-tumor efficacy and reduces the likelihood of quick resistance development, as cancer cells would need to adapt to disruptions in two distinct pathways simultaneously.

Clinical Implications of Dual Inhibition

The dual inhibition strategy of stenoparib may hold important clinical implications. By simultaneously targeting PARP and Tankyrase, Stenoparib could offer a promising therapeutic option for patients with advanced, recurrent ovarian cancer, particularly those who have exhausted other treatment options. This approach aligns with the principles of precision oncology, aiming to provide personalized treatment based on the genetic and molecular profile of the patient’s tumor. The interim results from the Phase 2 trial suggest the potential of stenoparib to improve clinical outcomes and offer new hope for patients battling ovarian cancer.

Future Prospects

The successful completion of the Phase 2 trial could pave the way for further clinical development of stenoparib, including potential Phase 3 trials. If approved, stenoparib could offer a new therapeutic option for patients with advanced ovarian cancer, particularly those who have exhausted other treatment options. Allarity Therapeutics is committed to advancing stenoparib through its clinical development pipeline, bringing this promising therapy to market, and improving patient outcomes.

The market for ovarian cancer treatments is substantial and growing, driven by the increasing incidence of the disease and advancements in therapeutic options. According to a report by Insight Ace Analytic, the global ovarian cancer market is expected to grow at a compound annual growth rate (CAGR) of 10% from 2023 to 2031.

Additionally, the global PARP inhibitors market was valued at $3.4 billion in 2023 and is projected to grow at a CAGR of 15%. The demand for effective treatments is particularly high for advanced, recurrent ovarian cancer, where existing therapies often fail to provide durable responses.

Source: Insight Ace Analytic

Stenoparib, with its dual inhibition strategy targeting both PARP and Tankyrase, addresses a significant unmet medical need in this market. Its therapeutic potential was highlighted in the recent Phase 2 clinical trial, which demonstrated clear clinical benefit, including tumor shrinkage and long-term disease stability in heavily pretreated ovarian cancer patients. These promising results have prompted Allarity Therapeutics to accelerate the development of a follow-on trial with FDA regulatory intent, potentially solidifying stenoparib’s market potential.

Competitive Landscape

The ovarian cancer treatment landscape is highly competitive, with several key players developing and marketing therapies, particularly PARP inhibitors. However, due to safety concerns, the PARP inhibitor market has faced setbacks, with major players withdrawing their drugs for specific indications. Despite these challenges, the market remains substantial and continues to attract significant investment. The PARP inhibitor market is expected to reach $22 billion in revenue by 2028, driven by ongoing advancements and the need for more effective and safer treatments.

Some of the major competitors and their key drugs include:

1. AstraZeneca plc

   • Drug: Lynparza (Olaparib)

     • Description: Lynparza is a well-established PARP inhibitor that has been approved for the treatment of BRCA-mutated ovarian cancer. It has shown significant efficacy in prolonging progression-free survival in patients. Lynparza is often used in both frontline and recurrent settings.

     • Market Position: As a market leader, Lynparza has a strong foothold, offering a solid efficacy profile and being widely recognized and adopted in clinical practice.

     • Recent Market Development: However, in August 2022, AstraZeneca and Merck voluntarily withdrew the indication for Olaparib in heavily pretreated BRCA-mutated ovarian cancer patients due to safety concerns from the SOLO3 trial.

2. GlaxoSmithKline plc (GSK)

   • Drug: Zejula (Niraparib)

     • Description: Zejula is a PARP inhibitor used for maintenance treatment in patients with ovarian cancer. It is approved for use in both BRCA-mutated and non-mutated ovarian cancer, providing a broader application compared to some other PARP inhibitors.

     • Market Position: Zejula’s broad approval makes it a strong competitor. Its ability to treat a wider range of patients enhances its market penetration.

     • Recent Market Development: However, GSK withdrew its indication for heavily pretreated BRCA-mutated ovarian cancer in September 2022 due to safety concerns.

3. Clovis Oncology, Inc.

   • Drug: Rubraca (Rucaparib)

     • Description: Rubraca is a PARP inhibitor used for treating advanced ovarian cancer. It is approved for patients with deleterious BRCA mutation (germline and/or somatic) associated with advanced ovarian cancer.

     • Market Position: While Rubraca is effective, it is primarily focused on BRCA-mutated cancers, similar to Lynparza.

     • Recent Market Development: Clovis Oncology withdrew its indication for rucaparib for heavily pretreated BRCA-mutated ovarian cancer in June 2022 following preliminary OS data from the ARIEL3 trial.

4. Merck & Co., Inc.

   • Drug: Keytruda (Pembrolizumab) and other pipeline assets

     • Description: While Keytruda is not a PARP inhibitor, Merck has been actively exploring its combination with PARP inhibitors to treat ovarian cancer. Their strategic focus includes enhancing the efficacy of existing therapies by combining them with their robust immuno-oncology portfolio.

     • Market Position: Merck’s extensive pipeline and strong presence in oncology make it a significant competitor in the ovarian cancer market.

Stenoparib’s Differentiation

Stenoparib sets itself apart in the competitive landscape through its unique mechanism of action, utilizing a dual inhibition strategy targeting both PARP and Tankyrase. This innovative approach offers a compelling therapeutic option in a market where other PARP inhibitors have faced significant challenges. By targeting these critical enzymes involved in cancer cell survival and proliferation, stenoparib provides a differentiated and potentially more effective treatment for patients with advanced ovarian cancer.

Additionally, stenoparib has demonstrated a favorable safety profile in clinical trials, with minimal significant side effects compared to first-generation PARP inhibitors, which faced safety issues leading to their withdrawal for heavily pretreated patients. This advantageous safety profile has allowed some patients to continue treatment with stenoparib for over 30 weeks, highlighting its potential as a next-generation treatment option for advanced ovarian cancer patients.

By focusing on developing this innovative therapy and leveraging its proprietary DRP® technology, Allarity Therapeutics seeks to position stenoparib as a differentiated and effective treatment option, potentially capturing a substantial market share and providing new hope for patients with advanced ovarian cancer.

Allarity Therapeutics is well-positioned to continue its clinical development programs, supported by a solid financial foundation. The company successfully raised funds and maintained a stable cash position, ensuring sufficient resources to advance its ongoing and planned clinical trials.

First Quarter 2024 Financial Highlights

• Research and Development (R&D) Expenses: For the quarter ended March 31, 2024, Allarity reported increased R&D expenses of $2.2 million, up from $1.4 million in the same quarter of 2023. The rise reflects higher manufacturing costs and an extension fee payment related to the license agreement for stenoparib.

• General and Administrative (G&A) Expenses: G&A expenses were $2.1 million for the quarter, a slight reduction from $2.2 million in the previous year, primarily due to lower insurance and professional fee expenses.

Balance Sheet Highlights

• Cash and Cash Equivalents: As of March 31, 2024, Allarity had $312,000 in cash, up from $166,000 as of December 31, 2023. As of July 19, 2024, Allarity had $20 million in cash, providing a financial runway into 2026, achieved through strategic equity raises and operational efficiency improvements.

• Total Assets: Total assets increased slightly to $11.969 million from $11.862 million at the end of 2023.

• Total Liabilities: Total liabilities rose to $18.440 million from $14.613 million at the end of 2023, driven by higher accounts payable and accrued liabilities.

Recent Strategic Developments

Allarity has made significant strides in securing its financial health and positioning itself for future growth:

• New Strong Cash Balance: Allarity Therapeutics now has a financial runway extending into 2026 with a cash balance above $20M, as of July 22, 2024.

• Pausing the At-The-Market (ATM) Offering: In line with the new financial position, Allarity plans to pause its ATM offering program for the foreseeable future.

• Capital Structure Cleanup: Allarity has consolidated to a single class of common stock and eliminated variable-priced convertible securities, including both warrants and Series A Preferred Stock.

• Operational Efficiency: The company has enhanced its operational efficiency and reduced its cost base.

• Focus on Stenoparib: Allarity has concentrated all company efforts on advancing stenoparib, the company’s promising clinical asset.

Allarity Therapeutics is guided by a team of seasoned professionals with extensive experience in biotechnology, finance, and clinical development. The leadership team's combined expertise is crucial in advancing Allarity's mission to develop innovative cancer treatments using their proprietary DRP® technology.

With a strong foundation in scientific research, operational management, and financial oversight, the team is well-equipped to drive the company's strategic initiatives and ensure the successful progression of its clinical programs.

Thomas Jensen, Chief Executive Officer, Founder